Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Journal of Controlled Release, 3(159), p. 362-367

DOI: 10.1016/j.jconrel.2012.02.030

Links

Tools

Export citation

Search in Google Scholar

Doxorubicin-conjugated chimeric polypeptide nanoparticles that respond to mild hyperthermia

Journal article published in 2012 by Jonathan R. McDaniel ORCID, Sarah R. MacEwan, Mark Dewhirst, Ashutosh Chilkoti
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

This paper reports the design, physicochemical characterization and in vitro cytotoxicity of a thermally responsive chimeric polypeptide (CP), derived from an elastin-like polypeptide (ELP). The CP self-assembles into ~40 nm diameter nanoparticles upon conjugation of multiple copies of doxorubicin (Dox), and displays a nanoparticle-to-aggregate phase transition between 39 and 42 °C in media, a temperature range suitable for mild hyperthermia of solid tumors. The CP-Dox nanoparticle is stable upon dilution to low micromolar concentrations, and is cytotoxic at both 37 and 42 °C. A thermally responsive nanoparticle formulation of Dox may prove to be broadly useful in hyperthermia targeted chemotherapy of a variety of solid tumors.